/PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company s special meeting of stockholders held.
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger
News provided by
Share this article
Share this article
ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ( Company, CBMG, we or our ), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company s stockholders vote
FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the merger proposal ).